Rosetta Genomics Ltd. provided earnings guidance for the six months ended June 30, 2015. The company is working to facilitate the completion and submission of its financial statements, and expects to do so on or before October 28, 2015 and expects to report unaudited pro forma revenue for the six months ended June 30, 2015 of approximately $4.0 million at that time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | -.--% |
2018 | Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd.. | CI |
2018 | Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 592 | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ROSGQ Stock
- News Rosetta Genomics Ltd.
- Rosetta Genomics Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2015